There are currently 145 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT04157127
Recruiting
This is a phase 1, first in man, dose escalation study for safety and feasibility for administration of 3 doses of DC vaccine for pancreatic adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas +2 locations
Conditions: Pancreatic Adenocarcinoma, Pancreatic Cancer
Register for Updates
Video Education With Result Dependent dIsclosure
NCT05225428
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Register for Updates
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
NCT02393703
Recruiting
The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether e... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Pancreatic Cancer, Benign Pancreatic Disease
Register for Updates
Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer
NCT05483075
Recruiting
Pilot study evaluating the feasibility of a 2-4 week health care provider guided exercise intervention prior to surgery for pancreatic cancer.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
11/08/2023
Locations: NYU Langone Health Ambulatory Care Center, New York, New York
Conditions: Pancreatic Cancer
Register for Updates
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
NCT05336266
Recruiting
The purpose of this study is to see if taking ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is reasonable, safe and can stabilize or increase weight along with quality of life in pancreatic cancer patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/05/2023
Locations: Cedars- Sinai Medical Center, Los Angeles, California
Conditions: Pancreas Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Register for Updates
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT04588025
Recruiting
The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
10/19/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Pancreatic Cancer
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT04683315
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/15/2023
Locations: HonorHealth Medical Group, Scottsdale, Arizona +1 locations
Conditions: Pancreatic Cancer
Register for Updates
Pancreatic Adenocarcinoma Gene Environment Risk Study
NCT00912717
Recruiting
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample. Some participants may also be asked to provide a urine sample. Individuals undergoing procedures that require collection of biological samples for clinical purposes may have these samples saved for research purposes. Participants will also be asked for their permission for study investigators to access medical records and/or recontact them for updates to their medical... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pancreatic Cancer
Register for Updates
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NCT02361320
Recruiting
This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Pancreatic Cancer
Register for Updates
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT05391126
Recruiting
This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (*1/*28) (heterozygotes) and usual UGT metabolizers (*1/*1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1 genotypes (*1/*28, *1/*1) will be randomized to genotype-guided dosing versus usual care.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Colorectal Cancer, Pancreatic Cancer
Register for Updates
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT02838836
Recruiting
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/28/2023
Locations: Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri
Conditions: Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Register for Updates